The May 2016 NAIT newsletter is available now – Please feel free to contact NAIT for any non-Ontario patients for the CDLK378X2103 study!

The May 2016 NAIT newsletter can be found here. 

The vision of the New Agents and Innovative Therapy Program (NAIT) supports The Garron Cancer Centre and SickKids’ commitment to innovation and providing Canadian children and their families living with cancer with greater access to the best and newest treatment that will assist to improve clinical care.

Contact NAIT for any non-Ontario patients for the study “A Phase I open label dose escalation study of LDK378 in pediatric patients with malignancies that have genetic alteration in anaplastic lymphoma kinase (ALK)”. https://clinicaltrials.gov/ct2/show/study/NCT01742286

HELPING FAMILIES NAVIGATE:  To assist patients and families with their transition, our Patient Navigator Program will collaborate with your team and the family to provide assistance with issues related to travel, accommodation, and navigating their way around the hospital and in the city. Furthermore, for patients living outside of Ontario, our Patient Navigator will assist physicians in completing an Out-of-Province Prior Approval Application to the Provincial Ministry of Health.

SickKids is one of only two centres in Canada offering MIBG therapy.
For more information, please visit
http://www.sickkids.ca/gfcc/mibg/index.html

Advertisements